Who founded YolTech Therapeutics?

YolTech Therapeutics was founded by Dr. Yuxuan Wu.

Who are YolTech Therapeutics's investors?

YolTech Therapeutics's investors include Decheng Capital.

YolTech Therapeutics

2 known investors

Find your way into YolTech Therapeutics

Paths you didn't know you had: your email and LinkedIn already hold routes to the YolTech Therapeutics team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

YolTech Therapeutics develops in vivo gene editing medicines using a proprietary lipid nanoparticle delivery platform to treat genetic, metabolic, and autoimmune diseases. The company operates clinical-stage programs targeting conditions including Transthyretin Amyloidosis, Alpha-1 Antitrypsin Deficiency, Primary Hyperoxaluria, Beta Thalassemia/Sickle Cell Disease, and Familial Hypercholesterolemia.

AI & Machine Learning Biotech Deep Tech Healthtech Medical Devices

Founders & leadership

Dr. Yuxuan WuCo-founder & CEO

Investors · 2

Decheng Capitallisted by Decheng CapitalMenlo Park

How we know: Decheng Capital's portfolio page · the VCSheet dataset · Not right? Tell us

Also in the syndicate · 1

AstraZeneca-CICClead

Funding

SEC filings, press & company announcements

Undisclosed amountSeries BSep 2025
AstraZeneca-CICC (lead)
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

In the news

YolTech Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for YOLT-101, an In Vivo Base Editing Therapy to Treat Heterozygous Familial Hypercholesterolemia (HeFH)prnewswire.com · Jun 2025

Frequently asked questions

What does YolTech Therapeutics do?: YolTech Therapeutics develops in vivo gene editing medicines using a proprietary lipid nanoparticle delivery platform to treat genetic, metabolic, and autoimmune diseases. The company operates clinical-stage programs targeting conditions including Transthyretin Amyloidosis, Alpha-1 Antitrypsin Deficiency, Primary Hyperoxaluria, Beta Thalassemia/Sickle Cell Disease, and Familial Hypercholesterolemia.
Who founded YolTech Therapeutics?: YolTech Therapeutics was founded by Dr. Yuxuan Wu.
Who are YolTech Therapeutics's investors?: YolTech Therapeutics's investors include Decheng Capital.